Interviews

Anne Cassity explains how Medicare Part D’s move to flat PBM service fees in 2028 may reduce incentives for high-cost formulary placement and support more cost-conscious medication decisions.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Anne Cassity of the NCPA outlines the historic passage of federal pharmacy benefit manager (PBM) reform and explains how new Medicare Part D contracting standards could reshape reimbursement and oversight for community pharmacies.

Derek Webb and Dennis Williams discuss key global learnings from the FIP World Congress of Pharmacy, highlighting how pharmacists worldwide are leading proactive OTC allergy care and what practical strategies US community pharmacies can adopt.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.

Pharmacists can use collaborative practice agreements in neurology to manage multiple sclerosis medications, labs, and expand care beyond disease-modifying therapies.

Learn how pharmacists cut GLP-1 costs, streamline prior authorizations, guide safe switches, and bust social media myths for lasting adherence.

Ann Marie Navar, MD, PhD, explains how enlicitide’s sustained LDL-C lowering, favorable tolerability, and structured dosing may improve adherence and expand oral add-on options for patients not at goal on statins.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

The VESALIUS-CV trial demonstrates that adding evolocumab to maximally tolerated statin therapy significantly reduces major cardiovascular events in both high-risk primary and secondary prevention patients.

Ongoing variation in vaccine schedule implementation requires pharmacists and clinicians to collaborate closely, reinforce evidence-based care, and monitor vulnerable populations for gaps in immunization coverage.

Pharmacists play a vital role in countering GLP-1 misinformation.

Changes to the federal childhood vaccine schedule have created confusion and variation in practice, placing added responsibility on clinicians and pharmacists to educate patients and ensure evidence-based care.

Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for patients with pancreatic cancer.

Joseph Saseen, PharmD, explains how persistent cholesterol myths undermine care and why emerging oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors could expand access to intensive LDL-C lowering.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Pharmacists play a critical role in improving access to and affordability of GLP-1 therapies.

Pharmacists play a vital role in managing multiple sclerosis treatments, enhancing patient care through clinical trials and personalized therapy options.

On Chen, MD; and Tahmid Rahman, MD, join Pharmacy Focus to discuss the world's first commercial administration of plozasiran at Stony Brook Medicine.

David Shusterman, MD, reveals how reducing alcohol enhances GLP-1 therapy, improving insulin regulation, kidney health, and overall metabolic outcomes.

Pharmacists play a vital role in supporting multiple sclerosis patients by addressing medication challenges, educating on treatments, and navigating insurance hurdles.

Experts say SMS-based engagement tools can help pharmacists improve medication adherence and reduce hospital readmissions by addressing common patient barriers such as forgetfulness and cost.